Pfizer Inc said its experimental breast cancer drug, in a mid-stage trial, showed a statistically significant improvement in patients' survival rates without their disease worsening.
The drug palbociclib was tested in post-menopausal patients in combination with the hormonal therapy letrozole, and results were compared with patients receiving only letrozole.
© 2026 Thomson/Reuters. All rights reserved.